-
An agreement has been signed between Bharat Biotech International Limited (BBIL) and BBio wherein BBIL will procure drug substances for the production of OPV to be supplied within India and globally.
-
The clinical trials are being carried out by Bharat Biotech in collaboration with Biofabri, the noted vaccine developer from Spain.
-
Genome Valley: It is home to more than 200 companies with a scientific workforce of about 20,000 professionals
-
Dr Krishna M Ella released a book “Economics of Covid-19- Digital Health, Education and Psychology” at his office at Hyderabad
-
It is the world's first intranasal Covid-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose.
-
The vaccine manufacturer had already received approval from the Central Drugs Standard Control Organisation (CDSCO) earlier this month for the nasal vaccine, the first of its kind in India.
-
NCOVACC is the world's first intranasal vaccine for COVID to receive approval for the primary two-dose schedule, and as a heterologous booster dose.
-
The availability of intranasal vaccine will strengthen the fight against the pandemic and broaden vaccine coverage.
-
Bharat Biotech on Monday announced that its iNCOVACC, its Covid vaccine in the form of nasal drops, has received approval from the CDSCO
-
New Delhi: India’s first intranasal Covid vaccine by Bharat Biotech on Tuesday got the approval from the Drug Controller General of India for 18+ age group for restricted use in emergency situation. Announcing the achievements, Union Health Minister Mansukh Mandaviya termed it a ‘big boost to India’s fight against Covid-19. “Big Boost to India’s Fight […]
-
Hyderabad: Hyderabad headquartered vaccine developer Bharat Biotech International Limited (BBIL) announced that its rotavirus oral vaccine Rotavac has been introduced by Nigeria to immunise its children from the life-threatening diarrhoeal disease. Nigeria currently accounts for 14% of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the […]
-
Hyderabad: Bharat Biotech completed clinical development for Phase III trials and booster doses for India’s first intranasal Covid vaccine – BBV154. Two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose (2-dose) schedule; and a heterologous booster dose for subjects who have previously received two doses of the two commonly […]
-
Hyderabad: Bharat Biotech International announced that its Covaxin has received emergency use approval in children aged between 6 and 12 years. It had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in the 2-18 age group. The clinical trials conducted in the paediatric […]
-
New Delhi: The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said. This development comes after the Subject Expert Committee discussed recommendations for the restricted emergency of Covaxin in […]
-
Hyderabad: Biotechnology company Ocugen will commercialise Bharat Biotech’s Covaxin in Mexico. The two companies amended their present co-development, supply and commercialisation agreement on Bharat Biotech’s Covid-19 vaccine Covaxin to include Mexico. With this amendment, Ocugen now has commercialisation rights of Covaxin for all of North America. “We’re excited to commercialise Covaxin in Mexico, as authorities […]
-
Hyderabad: A day before Covid vaccine booster shots become available to all adult population, prices of Covaxin and Covidshield have been reduced to Rs 225 per dose for private hospitals. Suchitra Ella, Co-Founder and Joint Managing Director of Covaxin maker Bharat Biotech announced the decision on the micro-blogging platform Twitter. “We welcome the decision to […]
-
New Delhi: Hyderabad-based vaccine manufacturer Bharat Biotech on Friday announced the temporary slowing down of its Covid vaccine Covaxin’s production across its manufacturing facilities. “Bharat Biotech today announces the temporary slowing down of production of Covaxin across its manufacturing facilities, having completed its supply obligations to procurement agencies and foreseeing the decrease in demand,” it […]
-
Hyderabad: Padma Bhushan awardees Dr Krishna Ella and Suchitra Ella had moved to the US in late 1980s with just two suitcases and 14 years later when they decided to return to India, they had come back with a 40 feet container. “This container did not have our personal belongings but 70 per cent of […]
-
Hyderabad: The next pandemic, if it comes, will be on the animal side and food security issues, predicted Krishna Ella, Founder and Chairman of Bharat Biotech, that created the Covaxin. “I predict that, if the next pandemic comes, it will be on the animal side and food security issues. We do not want it to […]
-
Hyderabad: When Bharat Biotech was looking at developing vaccines after the Covid outbreak, the highest priority was ensuring the safety in adult vaccination, Dr Krishna Ella, managing director, Bharat Biotech International noted on Thursday. Speaking at a panel session on the first day of BioAsia titled ‘Two years into the pandemic – Challenges, successes and […]